๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Sequential instillation therapy with mitomycin C and Adriamycin for superficial bladder cancer

โœ Scribed by Shigeo Isaka; Tatsuya Okano; Kohichi Abe; Jun Shimazaki

Publisher
Springer
Year
1992
Tongue
English
Weight
338 KB
Volume
30
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Sequential instillation therapy with mit
Sequential instillation therapy with mitomycin C and adriamycin for superficial bladder tumors
โœ Iwao Fukui; Hideaki Sekine; Kazunori Kihara; Takumi Yamada; Tsuneo Kawai; Makoto ๐Ÿ“‚ Article ๐Ÿ“… 1987 ๐Ÿ› Springer ๐ŸŒ English โš– 346 KB

From October 1983 to September 1985, 84 patients with superficial bladder tumor (Ta, Tl, Tis) were treated with sequential instillation of mitomycin C (MMC) and adriamycin (ADM). Doses of 20 mg MMC on day 1 and 40 mg ADM on day 2 were instilled into the bladder and retained for at least 2 h; this wa

Prophylactic intravesical instillation t
Prophylactic intravesical instillation therapy with adriamycin and mitomycin C in patients with superficial bladder cancer
โœ Tomoyasu Tsushima; Yosuke Matsumura; Yujiro Ozaki; Jun Yoshimoto; Hiroyuki Ohmor ๐Ÿ“‚ Article ๐Ÿ“… 1987 ๐Ÿ› Springer ๐ŸŒ English โš– 380 KB

Intravesical instillation of adriamycin (ADM) or mitomycin C (MMC) was carried out for the purpose of preventing the recurrence of superficial bladder cancers (Ta and T1) after transurethral resection or transurethral coagulation. First, eligible patients were divided into two groups (solitary and m

Prophylaxis of superficial bladder cance
Prophylaxis of superficial bladder cancer with instillation of adriamycin or mitomycin C
โœ Shigeo Isaka; Tatsuya Okano; Jun Shimazaki; Tatsuo Igarashi; Shino Murakami; Tsu ๐Ÿ“‚ Article ๐Ÿ“… 1987 ๐Ÿ› Springer ๐ŸŒ English โš– 278 KB

A multicenter trial for postoperative prophylaxis of superficial Ta-T1, G1-G2 bladder cancer was performed. Intravesical instillation using either 20-30 mg adriamycin or 20 mg mitomycin C per dose was carried out for 4 weeks or 2 years. Patients without instillation served as controls. A total of 25